- Imugene (ASX:IMU) announces that its B cell immunotherapy, HER-Vaxx, and CF33 oncolytic virotherapy CHECKVacc are being showcased at the ESMO Congress this week in Madrid
- IMU is a clinical-stage immuno-oncology company, that aims to contribute to the field and provide new treatment options and insights into managing challenging cancer types
- The ESMO Congress serves as the most influential oncology platform for clinicians, researchers, patient advocates, journalists, and healthcare industry representatives from around the world.
- Showcasing research and collaboration at an event such as the ESMO Congress, gives the company a high level of exposure in the market
- IMU last traded at 4.2 cents
Imugene (ASX:IMU) has announced that its B cell immunotherapy, HER-Vaxx, and CF33 oncolytic virotherapy CHECKVacc are being showcased at the ESMO Congress this week in Madrid.
Imugene, a clinical-stage immuno-oncology company, aims to contribute to the field and provide new treatment options and insights into managing challenging cancer types.
The European Society for Medical Oncology (ESMO) Congress serves as the most influential oncology platform for clinicians, researchers, patient advocates, journalists, and healthcare industry representatives from around the world.
HER-Vaxx
One presentation includes details on the phase two study involving HER-Vaxx (IMU-131), an immunotherapy specifically targeting HER2-positive advanced stomach cancer.
The study combines HER-Vaxx with standard chemotherapy, with a focus on assessing the production of anti-cancer antibodies and their correlation with improved clinical outcomes.
The company’s presentation will discuss the prevention of metastasis formation through combination therapy targeting HER2 and PD-L1 in HER2-expressing tumours.
The research suggests that effective vaccination against HER2-positive tumours may have therapeutic potential.
CF33 oncolytic virotherapy CHECKVacc
Imugene will introduce the use of the oncolytic virus CF33-hNIS-antiPD-L1 through intratumoral injection in patients with metastatic triple-negative breast cancer (mTNBC).
The study focused on inducing an inflammatory tumour microenvironment, which is considered a promising approach in treating this aggressive type of breast cancer.
Imugene’s studies represent a multifaceted approach to oncology treatment, incorporating immunotherapy, combination therapies, and oncolytic viruses.
Its showcase of research and collaboration at an event such as the ESMO Congress provides the company with a high level of exposure in the market.
IMU last traded at 4.2 cents.